• • • • • Semaphorin • • oligodendrocyte endothelial, and neuronal cells. SEMA4Dthrough signaling PLXNB1 induces growthcone collapse of neurons, inhibits differentiat maturation of OPCs, blocking SEMA4D could reduce the loss of ODs and promote and ODs loss of the reduce could SEMA4D maturation blocking OPCs, of could therefore reduce severitythe sclerosis of multiple throughseveral means. First, couldSEMA4Dreduce rat blocking the also playsSEMA4D an important role glial in • We havedemonstrated in several preclinical modelseffects the of centralin the SEMA4D system. nervous Inhibitoryeffects o maySEMA4Dblood brainblocking and (BBB), reducebarrier infiltrationcell immune into CNS. the reducing inflammationresponsessecondary immune and to antigens. CNS Second, to extent the mediatesthat SEMA4D apoptosisa implicated ingrowth tumor various angiogenesis.and Usingtumor models we demonstrated that anti interactionsSEMA4D soluble and both mouse, cellular rat,in PLXNB1 with monkey,through humans. and PLXNB1 signalingSEMA4D Antibody neutralizationrepresentsof SEMA4D newa therapeuticstrategy for sclerosis. multiple We selected humanized a IgG4 chronic EAEcharacterizedinflammation. axonalof myelin a by combination continuing and including loss and models, and in vivo, toand promote neural regeneration. Treatment anti with myelination 2012 subjects areand enrolled thirdin nowthe being dose cohort. with a of VX1 Infusions completed; been has tumors solid advanced with patients in trial clinical I Phase a of phase escalation dose A. Jonason, E. Klimatcheva , J. Veeraraghavan,J. , Klimatcheva E. Jonason, M. A.
The Objective Experimental Large mouse Results
soluble form upon cell activation cell form upon soluble SEMA4D is expressed the surfaceabundantlyon of resting cells lessstronglyand T APCs, cells is onB and and upregulated TherapeuticRationale: Neutralization SEMA4Dantibodymonoclonalof Sclerosis aMultiple using couldinhibit progression by s Results stained were samples forFFPE macrophage (F4/80), Objective SEMA4Dthrough signaling Plexin SEMA4Dthrough signaling CD72 SEMA4Daffinity ahigh has (1 Experimental Design To histochemical markersobserve Spinal SEMA4D glycoprotein infiltrating experiments MAb Epitope SEMA Affinity
independent anti Similar data observed with with dataobserved Similar by way one (**p<0.01 ANOVA). Similar resultsobservedin twoadditional studies with 1x 1x week600 with per Results were beginning dosedDay on mg/kg 2X/week 7(~30 600ug/antibody with EAE was induced in EAE was induced in miceSJL Objective Objective Experimental Design model. EAEMOG Toanti test the Experimental Design We observed approximately a 25% reduction in clinical score in the the in clinical scorein reduction We approximately25% observed a Results To if determine A A 50% reduction in clinical score was observed for the
presence areas Development of an anti an Development of
67- maximum administered dose
IgG
cords 4
2 D
- To .
of / mapping
and
macrophage - of by
NaïveRat Brain(untreated)
mice do not develop EAE in response to immunization with myelin peptide
have shown been using recombinant SEMA4D, and anti
determine
4D (SEMA4D/CD100) is expressed4D (SEMA4D/CD100) on mostaffinity itshighcells, and immune receptor, Design
have of MAb (MAG) from antibody SJL Relapsing Anti
isotype flow
- drug SEMA4D antibody antibody SEMA4D
MAb precursorcellsinduces (OPCs),
-
yielded
SEMA4D antibody and in two other labs. otherSEMA4D two in antibody and
MAb
67
cytometry male B6 male SEMA4D staining shows was
B6 MOG EAE MOG B6
control ------67-
penetration - ug
by origin 2 SEMA4D Protects-SEMA4D Against
KO maintain the integrity of the BBB, thereby reducing T cell infiltration into the CNS into infiltration cell the T BBB, the reducing thereby of integrity maintain the reduce severity disease of byblockinginhibition inhibits inhibits activates activates endothelial cells activates endothelial induces apoptosisinduces ofoligodendrocyte B cell aggregation and differentiation and aggregation cell B reducerelapse rateby reducing
67-
2 is effective2 in a relapsing detected (~30 mg/kg) antibody, n mg/kg) (~30 similar and if IHC Anti SEMA4D is Capableof Penetrating theCNS MAb
2
that mice with MOG with mice - . with PLP with when
Images treated treated VX
MAb .
67-
neurite nM results
Anti-SEMA4D-treated Isotype- treated oligodendrocyte for myelin and macrophage/microglia in spinal cords of Th1 adoptively transferred SJL EAE mice
It
the Generation of Anti 15 neuroinflammatory MAb in
in Anti
compared
2 dosing 1X/week and every other week other everyand 1X/weekdosing 2 - is
the
) PLXNB1) Receptor a lowaffinity and (300 67-
B1 /2503 FFPE 139- animals
shown possible animals
MAb . 67-
of 20 mg/kg. A randomized,of 20 mg/kg. placebo
2 CNS 151 Giralico, J. Seils, H. Bussler, H. Seils, Giralico, J. Torno, S. Leonard,J. W.J.M. Paris, Evans, E. M. Zauderer, Bowers, Smith E. Arrows
extension axonal and regeneration can
-
sections
2 for its ability to reduce EAE scores in the B6 the in scoresEAE reduceto ability its for 2 in in CFA. S Remitting EAE Remitting
35-
is . were be -Sema4D Reduces EAE for
67
55
with
showed
approximately peptide CFA in Pertussis with Toxin;Mice
indicate
-
isotype that detected =18/group =18/group 2 cell activation cell mayand of responses. Tcell induction Band influence Antibodyneutralization of SEMA4D H&E
seen
Myelination
using and - process collapse isotype tarting tarting dayon 7, were mice injected remitting SJL EAE model remittingEAE SJL
oligodendrocyte
conformational MAb
MAb
for
a
and VX microglial a a
reactive rat mouse, with , primate ,
in
lesion decrease
rat 67- - MAb 67- neuroinflammation 15
treated
Perform generateand fusion a the MAb panel of mouse hybridomas hybridomas mouse of panel - adsorbed /2503 2 as well as with another another with as as well 2
2 treated2 group. (MAG), and general (H&E). histology and (MAG),
67-
CNS in
5
precursor cells 67 and human SEMA4D
MAb
the
nM 2 EAE (Control Rat Brain cells animals of in -
VX15/2503 2
and share Introduction
MAb IgG Control
treated spinal macrophage/microglial EAE
(Human IgG4)
67- goat
as
changes
(OD) process collapseand apoptosis, and disrupts tightCNS endothelial junctions. isotype ), n=14/group ),
-2 67 Abstract 2 treated2 group . rats measured -
SEMA4D antibody has been shownto has antibodybeen protectSEMA4D integritythe both in v of BBB the the The anti cord remyelination
- conditions
. SEMA4D SEMA4D
-mouse
-
control and secondary immuneresponsesand toantigens CNS same
mouse majority
white in nM - controlled, single ascending dose Phase Phase 1dose studycontrolled, patientsascending in MS single beganin
the ) CD72 Receptor)
- by epitope matter
treated MAG antibody
are MAbs
recombinant Microglial of
Biacore remyelination
from and axonal and regeneration
F
IgG staining Results Results peak disease toup weeklytwice Units Units were injected EAE is induced in Dark Agouti ratsMOG induced Dark in with EAEis control transfer,post atdayStarting 0 injected were mice Objective Objective Experimental Design scores Agouti in rat Dark chronic EAE model. Toanti test the Experimental Design in the Th1 adoptive transfer EAEmodel in SJLmice. Toanti test the group (**p<0.01 by two waytwo by ANOVA) group (**p<0.01 the for observed was scoreclinical in drop significant A for both Significant reduction in EAE score (p<0.05 using one way ANOVA) was observed
4 of
/
EAE . 80- also attenuates the disease severityin several rodent EAE .
This the animals
)
rmuIFN
SEMA4D MAbs positive
animals,
on
Humanize Clinical Scores IgG isotype
MAb
(F
antibody
4 protein or 600ug or recombinant
/ sacrificed 80 - 67-
. . Third,maySEMA4D play a rolein breakdown of the Doherty β. Vaccinex i.p
cells - -
SJL Adoptive TransferEAE AdoptiveSJL but ) control SEMA4D antibody antibody SEMA4D antibody SEMA4D
N=12/group . with 15 mg/kg of MAb of mg/kg 15 . with
as - IFN and 2
Plexin
not does
were account
well
anti
- Activationin EAE at untreated - specificity, affinity,and functional SEMA4D antibody inhibits thes antibody inhibits SEMA4D treated
Screen panel of hybridomas for
not Chronic Rat EAE Rat Chronic
or
-
- as
SEMA4D SEMA4D CD B1 (PLXNB1), is expressedB1 (PLXNB1), on dendritic
SEMA beta controlgroups, not but as
detect a 45 SEMA4D monoclonal antibody for the treatmentfor antibody of monoclonal SEMA4D , Inc. Rochester,www.vaccinex.com NY
close for MAb 67- MAb , Reilly,C. T. Fisher, L. Winter, Mallow,, Crystal ,R. Kirk, C. Howell, Cornelius, A. S.
decrease animal
EAE Rat Brain (Anti (Mouse IgG1) , then weekly thereafter. weeklythen ,
low
naïve F4/80
4 MAb MAb the
MAb D rat to (not
. and
the Similar
difference
activity IgG animals 67- 67- and secreted and as a biologically active
67 (~30 mg/kg), or 3X/week with 1,000 with 3X/week or mg/kg), 67(~30 67-
in
shown),
group 2 for its ability to reduceEAE 2 for its ability to reduceEAE scores
but
0 2 or an an 2 or irrelevant murine
1 demyelination
eve - . 125 5
5/2 . readily
white
2
nM e o
in IFA.in Starting at dayrats3,
ral mechanisms mean n O i.p
. 503 were503 tolerated,well
indicating
f disease relapse by Multiple Sclerosis
. . an
on D differentiationD and weekly with either 600 either with weekly ion of of ion matter
-
identifies MAb SEMA4D) score tibody thatblockstibody IgG
native nd
. e processes. e The has also been also been has by 67-
areas as inhibits inhibits
microglial myelin
2 treated
possible
the
cell
are
presence
IgG - -
bound associated shown ,
. Several
and 500 µm itro ug
not
for of
OPC Results 0 (**p< Experimental differentiation Activated Objective To VX Results on representative animal spinal cord mid cord representativespinal animal on Bruker receivedid receive but notLPC,did (n=6) Focal Objective Experimental Design Anti later, an • • • Non • • Non • • • • Immunotoxicology • Toevaluate effect the of MAb 67-2 (Rat #7) MAb 2B8 (Rat #15) • • Clinical 15 -SEMA4DAnti Enhances Remyelination ina Lysolecithin determine reveals were Glutaradehyde Objective To Distinct Results Experimental area
shown toactivity functional blockthe of VX15/2503 producedcharacterized and toprior manufacture of antibody for in use A 3 3 differentiation
Lesion Vol= 0.45 mm Lesion Vol= 0.68 mm / - evaluate 2503 SEMA4D SEMA4D stable CHO - - . Study Day
demyelination determined The All completed – Chronic – Subchronic – were VX Saturation VX positive prior An remarkably influenza significantly 05, clinical clinical of Phase and The continuing tolerability, advanced
BioSpin derived
caspase intrathecal
15/ 15/
A. animals
influenza Bonfer
Myelin that
significantly regions
(2 µl 1%)
macaques mg/kg/dose month A Rat A iv mg/kg/dose
no
Design exposed Lyso pharmacokinetics to dose
2503 2503
if (B)
A. GLP
0
quantitateand MAb treatment enhances spinal cordrepair in similar relative I,
Toxicology Toxicology
doses Dose
instrument. The regionthe spinal of cord containing lesion wasthe dissected and out processedforfurtherhistological exam
control
influenza VX
Design from is a a is and
roni’s
multicenter, - observed in 3 Dorsal column Dorsal - .
fixed
15/
solid
S cell line expressinglinecell S wasVX15/2503 constructedcharacterized; and a master bank was cell similarly
study of
virus
displayed 6-
Toxicology results staining
escalation similar
was for DFR
repeat
delayed catheterfilledeither with
to All authors are employees of employees are authors All did pharmacokinetics
high host
was induced by stereotactic infusion 2 µL 1%of of
month cynomolgus
5 Toxicology demyelination 2503
to Implant to
Multiple
six
Alzet spinal serial reduced this
of be
was
using tumors
2
dosed naïve significant -
intrathecal
not
in **** resistance affinity affinity
Rat OPC Apoptosis Rat
at SEMA4D Protects Against -SEMA4DAnti
delivery,
month
Summary Studies
the between
VX protects was
appear
. trial dose completed
rats
sections myelination
viral
toxicology
adverse cords algorithms 3 dose 15/
animals
alter randomized, any VX15/2503
Comparison
phase highest
performed both
Development of an antiDevelopment an of at . has
of
Mab (90 µg/dayviaAlzetPump)
GLP 2503 humanizedantibody that was derivedfrom MAb the mouse 67 clearance
toxicology
macaques from
0
dependent
are - MAb67
intravenous
rat MAb MAb dexamethasone
; drug
to been dose of Sema species
model
the
10; loss toxicology
of
effect
5 apparent
OPCs
- and
generated
be dose EAE 67- 2B8: Group Mean = 0.66 mm study intrathecal lesion sections for MBP to identify demyelinated areas and Iba1 for microglial activati microglial for Iba1 demyelinatedand areasidentify to MBP for sections lesion in at
descending
of levels
4 100;
ability a to completed
Test)
dorsal 2: 2: GroupMean = 0.40 mm 2 or control antibody, MAb2B8, in a spinal D
dose level, .
0 pharmacodynamics was
rats MAb double - myelin Phase detect
from
;
administered
study
induced were
employed
level PK both the cellular solubleand forms of SEMA4D or
30;
funicular were in
performed 67-
VX
studies in
Vaccinex.Copyright
of dependent
SEMA 200 in MAb is
spinal
apoptotic
dexamethasone -
15/ Image levels I, 50 µm dosed
2 (n=9) or MAb or 2 (n=9) blind,
100
in
approximately all was
. processed (NOAEL) rats
apoptosis
non
B.
mg/kg/dose 2503
2B8 for2B814 days. volumes weresubsequently determinedLesion by MRI using a 3D cynomolgus 4 studies
;
Ex vivo vivo Ex
cords
D
region
Blocks Pro
26
MRI separated lysolecithin up
used
-
Harvest placebo induced during to
randomized,
in or in
B. weekly cells
to
14 and in software
of
3 rats clear
each 3
for
of
as and was and 100 200
patients
of
Naïve rats spinal and
2B8 (n=11) and and 2B8 (n=11) attached to 3 EM 1
a weekly - lysophosphatidylcholine by apoptosis - controlled,
- inhibition fold
lesioned rats.lesioned
treated
MBP .
2013 Vaccinex 2
and mM
cords higher Rat OPC Differentiation Rat OPC
open
with Toluidine staining
SEMA4D within
intravenous
with
(A) of of Group Mean SEMA4D SaturationToxicology) (Rat 6 month SEMA4D Mean Group
in non
Multiple
anti ascending label, differentiation
IBA-1 MBP and
IgG
control
the lysophosphatidylcholine Influenza Clearance in Rats After Vx15/2503 Dose Vx15/2503 Rats in After Clearance Influenza was
MRI Lesion Vol. Lesion MRI 0mm - - Blue clinical and clinical clinical and clinical SEMA
- Optic Nerve Spinal Cord permission by Used reserved. rights , Inc. All
treated reverses lumbar
No lesion Rat 32 Rat No lesion used -SEMA4D Humanized dose
staining
IgG Sclerosis 4
infusions (LPC;
D
single C.
as treated
. animals Alzet - spinal
escalation Myelin inhibition
a lysolecithin . in
marker in a varietyin of DFR Control Control induced OPC ToxicityOPC -induced minipump
-
rat dose
cord -
began of 2 antibody.It has been
EAE compared Control
is
in OPC
VX Demyelination
preserved
(total 100
of of
studies. study rats
(LPC) lesion model of focal of model lesion (LPC) study 15/ 3
) directly into the dorsal column (T9/T10level) ofrat spinal cords. Twodays
in
was implanted to deliver 90 µg µg was implanted 90to deliver . IgG 1
µm of 2503
to late of
25 in vitro in
anti
to IgG Toluidine
in the
MRI Lesion Vol. Lesion MRI mm 0.68 images/rat)
in 2012. anti evaluate - C. SEMA
adult safety,
on. on. - assays. SEMA Anna SEMA Brain lysolecithin 2b8 Rat 18 2b8Rat Mab
Blue 4
Enrollment D patients
treated Williams . 4 4 VX15/2503 Slice tolerability,
the Myelination D D sections
SEMA4D
treated
D. blocks - demyelination Model safety, induced injury ina
TrueFISP Anti with animals
at
tion.
were
is Edinburgh University) spinal
MAb Anti
(in remyelination index
MAb Immunohistochemistry
in EAE Lesion -induced
. N N 3 imaged sequence of 1 of sequence -
collaboration
- “****” /day fordays.14 controlSham rats
SEMA4D SEMA4D cords
was
in rats in
MRI Lesion Vol. Lesion MRI mm 0.45 N Y
. in
at determined
indicates Quantitation
. 60x
an
Y Y
67 Rat 7 67Rat Mab
following
- with in
h duration a 7T on for
p< vitro
each
Dr by 0 .
0001. of
was performed
quantitating
group all
images
and
3